Shots:
- CB Biotechnology has entered into a definitive agreement to acquire Theratechnologies, delisting it from public markets
- As per the deal, Theratechnologies’ shareholders will receive $3.01/share in cash & a non-tradeable CVR of $1.19/share tied to company milestones, with total CVR payments limited to $65M, making it an aggregate of $254M, assuming full CVR payout; closing expected in company’s Q4 ending Nov 30, 25
- CVR holders will receive 50% of Egrifta (tesamorelin) gross profit exceeding $40M, if profit surpasses such figure for each 12mos. period ending 12, 24, & 36mos. post-closing. Also, CVR holders will receive $10M if cumulative Egrifta profit exceeds $150M & $15M if combined Egrifta & Trogarzo (ibalizumab) profit exceeds $250M over 36mos.
Ref: Globenewswire | Image: Thera Technologies| Press Release
Related News:- BioVersys Partners with Shionogi to Jointly Develop Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
